Documentation is one of the largest hidden costs in procedural medicine.
It drains physician time, delays reporting, and adds operational friction.
Most systems solving this problem were built decades ago — and patched forward.
INVESTORS
Synexar is a workflow-native clinical documentation platform focused on solving a real problem — and scaling it carefully.
THE PROBLEM
Documentation is one of the largest hidden costs in procedural medicine.
It drains physician time, delays reporting, and adds operational friction.
Most systems solving this problem were built decades ago — and patched forward.
The burden is real. The workflows have not caught up.
TIMING
Healthcare systems are being forced to modernize documentation infrastructure.
Physician tolerance for inefficient tools is declining.
AI is now mature enough to assist — but only when applied with restraint.
The opportunity is not new technology. It is correct application.
APPROACH
Synexar is designed around when documentation actually happens.
Immediately after the procedure.
While context is still intact.
Speed is a consequence of predictability.
DEFENSIBILITY
This is not a consumer tool. Reliability compounds.
BUSINESS MODEL
Pricing aligns with clinical environments, not usage gimmicks.
Facilities pay for predictable capability, not variable behavior.
Revenue scales with deployment footprint, not individual users.
This creates stable ARR without operational complexity.
CAPITAL EFFICIENCY
Synexar is built by a small, senior team.
Engineering is focused on leverage, not headcount.
Hiring is tied to revenue milestones, not optimism.
We optimize for durability, not speed at all costs.
TEAM
Synexar was founded by a practicing gastroenterologist and a senior technologist.
The problem is lived daily — not abstracted from interviews.
Product decisions are driven by clinical reality and technical feasibility.
We build what we would deploy ourselves.
DISCIPLINE
In healthcare, restraint is a competitive advantage.
DEPLOYABILITY
Deployability matters more than novelty.
We are focused on steady execution and long-term value creation. If you value disciplined growth over hype cycles, we should talk.
Investor inquiry